Drug Trial Radar · NCT04994509
Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection
Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
5,368
Actual
Start
Aug 30, 2021
Primary completion
May 27, 2024
Study completion Jan 2028
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Aug 6, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 16 years, up to 25 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this study is to evaluate the efficacy of the study drugs, lenacapavir (LEN) and emtricitabine/tenofovir alafenamide (F/TAF) in preventing HIV infection, in adolescent girls and young women (AGYW). The primary objective of this study is to evaluate the efficacy of LEN and F/TAF for HIV-1 PrEP in AGYW at risk of HIV-1 infection.
Conditions
- Pre-Exposure Prophylaxis of HIV Infection
Interventions
Oral Lenacapavir (LEN)Drug
Tablets administered orally without regard to food
Subcutaneous (SC) Lenacapavir (LEN)Drug
Administered via SC injections
F/TAFDrug
Tablets administered orally
F/TDFDrug
Tablets administered orally
Placebo SC LENDrug
Administered via SC injections
PTM Oral LENDrug
Tablets administered orally
PTM F/TAFDrug
Tablets administered orally
PTM F/TDFDrug
Tablets administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence Phase: Recent Infection Testing Algorithm (RITA) Estimate of the Background Human Immunodeficiency-1 Virus Infection Incidence Rate (bHIV) Per 100 Person Years (PY)Time frame: Incidence Phase Screening Visit (Day 1)
- Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN and F/TAF Compared to Participants in All Screened SetTime frame: When at least 50% of the participants completed 52 weeks of follow-up after randomization or permanently discontinued from the study (maximum 143 weeks)
Locations
28 sites in 2 countries. Site status is shown where the registry gives one.
Madibeng Centre for Research
Brits, South Africa
Emavundleni Research Centre
Cape Town, South Africa
Vuka Research Clinic
Cape Town, South Africa
Desmond Tutu Health Foundation Clinical Trials Unit
Cape Town, South Africa
Botha's Hill Clinical Research Site, HIV Prevention Research Unit
Durban, South Africa
CAPRISA eThekwini Clinical Research Site
Durban, South Africa
CAPRISA Vulindlela Clinical Research Site
Durban, South Africa
MatCH Research Unit, Suite 1112, 11th Floor
Durban, South Africa
Synergy Biomed Research Institute (SBRI)
East London, South Africa
Setshaba Research Centre
Gauteng, South Africa
Wits Reproductive Health & HIV Institute (Wits RHI)
Johannesburg, South Africa
The Aurum Institute: Gavin J Churchyard Legacy Centre, Klerksdorp Clinical Research Centre
Klerksdorp, South Africa
Perinatal HIV Research Unit (PHRU) Soweto Kliptown
Kliptown, South Africa
Phoenix Clinical Research Site, South African Medical Research Council, HIV and Other Infectious Disease Research Unit
Kwa Zulu Natal, South Africa
Verulam Clinical Research Site, South African Medical Research Council, HIV and Other Infectious Disease Research Unit
Kwa Zulu Natal, South Africa
Tongaat Clinical Research Site, South African Medical Research Council, HIV and Other Infectious Disease Research Unit
Kwa Zulu Natal, South Africa
Chatsworth Clinical Research Site, South African Medical Research Council, HIV and Other Infectious Disease Research Unit
Kwa Zulu Natal, South Africa
Qhakaza Mbokodo Research Clinic
Ladysmith, South Africa
Africa Health Research Institute
Mtubatuba, South Africa
The Aurum Institute: Pretoria Clinical Research Centre
Pretoria, South Africa
The Aurum Institute: Rustenburg Clinical Research Centre
Rustenburg, South Africa
Desmond Tutu Health Foundation - Masiphumelele Research Office
Sunnydale, South Africa
The Aurum Institute: Tembisa Clinical Research Centre
Tembisa, South Africa
CAPRISA Umlazi Clinical Research Site
Umlazi, South Africa
FPD-DTHF Ndevana Community Research Site
Vincent, South Africa
Makerere-Kalangala Clinical Research site
Kalangala, Uganda
AMBSO Masaka Clinical Research site
Kyotera- Masaka Region, Uganda
Makerere University- John Hopkins University (MU-JHU) Mityana Research Site (MU-JHU) Care Ltd
Mityana Town, Uganda
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.